<?xml version='1.0' encoding='utf-8'?>
<document id="24285759"><sentence text="Bleeding events following concurrent use of warfarin and oseltamivir by Medicare beneficiaries."><entity charOffset="44-52" id="DDI-PubMed.24285759.s1.e0" text="warfarin" /><entity charOffset="57-68" id="DDI-PubMed.24285759.s1.e1" text="oseltamivir" /><pair ddi="false" e1="DDI-PubMed.24285759.s1.e0" e2="DDI-PubMed.24285759.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24285759.s1.e0" e2="DDI-PubMed.24285759.s1.e1" /></sentence><sentence text="During the 2009 H1N1 influenza pandemic, the UK Medicines and Healthcare Products Regulatory Agency received case reports suggesting a potentiation of warfarin anticoagulation by the antiviral drug oseltamivir"><entity charOffset="198-209" id="DDI-PubMed.24285759.s2.e0" text="oseltamivir" /></sentence><sentence text=" We evaluated this putative interaction using Medicare data" /><sentence text="" /><sentence text="To determine the frequency of bleeding following addition of oseltamivir or comparator drugs among Medicare beneficiaries taking warfarin"><entity charOffset="61-72" id="DDI-PubMed.24285759.s5.e0" text="oseltamivir" /><entity charOffset="129-137" id="DDI-PubMed.24285759.s5.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.24285759.s5.e0" e2="DDI-PubMed.24285759.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24285759.s5.e0" e2="DDI-PubMed.24285759.s5.e1" /></sentence><sentence text="" /><sentence text="This was a retrospective cohort evaluation using Medicare nationwide data" /><sentence text=" Cohort members were Medicare Parts A, B, and D beneficiaries from June 30, 2006 to October 31, 2010 receiving warfarin for at least 1 month prior to a concomitant drug of interest (oseltamivir, ampicillin, trimethoprim-sulfamethoxazole (TMP-SMX), and angiotensin-converting enzyme (ACE) inhibitors)"><entity charOffset="182-193" id="DDI-PubMed.24285759.s8.e0" text="oseltamivir" /><entity charOffset="195-205" id="DDI-PubMed.24285759.s8.e1" text="ampicillin" /><entity charOffset="207-219" id="DDI-PubMed.24285759.s8.e2" text="trimethoprim" /><entity charOffset="220-236" id="DDI-PubMed.24285759.s8.e3" text="sulfamethoxazole" /><entity charOffset="238-245" id="DDI-PubMed.24285759.s8.e4" text="TMP-SMX" /><entity charOffset="252-263" id="DDI-PubMed.24285759.s8.e5" text="angiotensin" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e0" e2="DDI-PubMed.24285759.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e0" e2="DDI-PubMed.24285759.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e0" e2="DDI-PubMed.24285759.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e0" e2="DDI-PubMed.24285759.s8.e3" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e0" e2="DDI-PubMed.24285759.s8.e4" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e0" e2="DDI-PubMed.24285759.s8.e5" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e1" e2="DDI-PubMed.24285759.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e1" e2="DDI-PubMed.24285759.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e1" e2="DDI-PubMed.24285759.s8.e3" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e1" e2="DDI-PubMed.24285759.s8.e4" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e1" e2="DDI-PubMed.24285759.s8.e5" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e2" e2="DDI-PubMed.24285759.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e2" e2="DDI-PubMed.24285759.s8.e3" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e2" e2="DDI-PubMed.24285759.s8.e4" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e2" e2="DDI-PubMed.24285759.s8.e5" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e3" e2="DDI-PubMed.24285759.s8.e3" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e3" e2="DDI-PubMed.24285759.s8.e4" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e3" e2="DDI-PubMed.24285759.s8.e5" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e4" e2="DDI-PubMed.24285759.s8.e4" /><pair ddi="false" e1="DDI-PubMed.24285759.s8.e4" e2="DDI-PubMed.24285759.s8.e5" /></sentence><sentence text=" Bleeding within 14 days of new prescriptions for oseltamivir or comparators was identified using inpatient or emergency department ICD-9 (International Classification of Diseases, ninth revision) discharge diagnosis codes for gastrointestinal hemorrhage, epistaxis, hematuria, and intracranial bleeding"><entity charOffset="50-61" id="DDI-PubMed.24285759.s9.e0" text="oseltamivir" /></sentence><sentence text=" Patients with bleeding within 30 days preceding the prescription concomitant to warfarin were excluded" /><sentence text="" /><sentence text="With concomitant ACE inhibitors as reference, adjusted odds ratios (ORs) for any bleeding events within 14 days were 1" /><sentence text="47 (95% confidence interval [CI] = 1" /><sentence text="08-1" /><sentence text="88), 1" /><sentence text="24 (95% CI = 0" /><sentence text="97-1" /><sentence text="57), and 2" /><sentence text="74 (95% CI = 2" /><sentence text="53-3" /><sentence text="03), for warfarin plus ampicillin, oseltamivir, and TMP-SMX, respectively"><entity charOffset="23-33" id="DDI-PubMed.24285759.s21.e0" text="ampicillin" /><entity charOffset="35-46" id="DDI-PubMed.24285759.s21.e1" text="oseltamivir" /><entity charOffset="52-59" id="DDI-PubMed.24285759.s21.e2" text="TMP-SMX" /><pair ddi="false" e1="DDI-PubMed.24285759.s21.e0" e2="DDI-PubMed.24285759.s21.e0" /><pair ddi="false" e1="DDI-PubMed.24285759.s21.e0" e2="DDI-PubMed.24285759.s21.e1" /><pair ddi="false" e1="DDI-PubMed.24285759.s21.e0" e2="DDI-PubMed.24285759.s21.e2" /><pair ddi="false" e1="DDI-PubMed.24285759.s21.e1" e2="DDI-PubMed.24285759.s21.e1" /><pair ddi="false" e1="DDI-PubMed.24285759.s21.e1" e2="DDI-PubMed.24285759.s21.e2" /></sentence><sentence text=" In a sensitivity analysis, adjusted ORs over a 7-day period were 1" /><sentence text="89 (95% CI = 1" /><sentence text="29-2" /><sentence text="59), 1" /><sentence text="47 (95% CI = 1" /><sentence text="06-2" /><sentence text="02), and 3" /><sentence text="07 (95% CI = 2" /><sentence text="76-3" /><sentence text="49) for warfarin plus ampicillin, oseltamivir, and TMP-SMX, respectively"><entity charOffset="22-32" id="DDI-PubMed.24285759.s31.e0" text="ampicillin" /><entity charOffset="34-45" id="DDI-PubMed.24285759.s31.e1" text="oseltamivir" /><entity charOffset="51-58" id="DDI-PubMed.24285759.s31.e2" text="TMP-SMX" /><pair ddi="false" e1="DDI-PubMed.24285759.s31.e0" e2="DDI-PubMed.24285759.s31.e0" /><pair ddi="false" e1="DDI-PubMed.24285759.s31.e0" e2="DDI-PubMed.24285759.s31.e1" /><pair ddi="false" e1="DDI-PubMed.24285759.s31.e0" e2="DDI-PubMed.24285759.s31.e2" /><pair ddi="false" e1="DDI-PubMed.24285759.s31.e1" e2="DDI-PubMed.24285759.s31.e1" /><pair ddi="false" e1="DDI-PubMed.24285759.s31.e1" e2="DDI-PubMed.24285759.s31.e2" /></sentence><sentence text="" /><sentence text="Bleeding with oseltamivir plus warfarin was not significantly increased over a 14-day observation period; a sensitivity analysis showed a statistically significant increase over a 7-day period; in contrast, the data consistently showed the known tendency of TMP-SMX to potentiate the effects of warfarin"><entity charOffset="14-25" id="DDI-PubMed.24285759.s33.e0" text="oseltamivir" /></sentence><sentence text=" The results should be interpreted with the limitations of this approach in mind, including the inability to control for unmeasured confounders" /><sentence text="" /></document>